Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 45Cyclophosphamide 32Lenalidomide 24fludarabine 20zanubrutinib 13venetoclax 12obinutuzumab 12orelabrutinib 11fludarabine phosphate 10Bendamustine Hydrochloride 10Magnetic Resonance Spectroscopy 9Whole-Body Irradiation 8Prednisone 8pirtobrutinib 7ibrutinib 7Vincristine 7Specimen Handling 7CT-P10 7Mycophenolic Acid 6Biopsy 6Doxorubicin 5tafasitamab 4pembrolizumab 3acalabrutinib 3Tacrolimus 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Melphalan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × voruciclib × 1 year × Clear all
NCT03547115 2026-03-17

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

MEI Pharma, Inc.

Phase 1 Terminated
84 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡